Product nameAnti-TNF Receptor II antibody [EPR1653] (HRP)
See all TNF Receptor II primary antibodies
DescriptionRabbit monoclonal [EPR1653] to TNF Receptor II (HRP)
Tested applicationsSuitable for: IHC-P, WBmore details
Species reactivityReacts with: Human
Predicted to work with: Mouse, Rat
- WB: Jurkat, MCF7, SW480 and THP1 whole cell lysates IHC-P: normal human kidney tissue.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Stable for 12 months at -20°C. Store In the Dark.
Storage bufferpH: 7.40
Preservative: 0.1% Proclin
Constituents: 30% Glycerol, 1% BSA, PBS
Concentration information loading...
PurityProtein A purified
- Anti-TNF Receptor II antibody [EPR1653] (ab109322)
- Anti-TNF Receptor II antibody [EPR1653] (Alexa Fluor® 488) (ab199821)
- Anti-TNF Receptor II antibody [EPR1653] (Alexa Fluor® 647) (ab199822)
- Anti-TNF Receptor II antibody [EPR1653] (Phycoerythrin) (ab209582)
- Anti-TNF Receptor II antibody [EPR1653] (PerCP) (ab220515)
- Anti-TNF Receptor II antibody [EPR1653] - Low endotoxin, Azide free (ab221921)
Immunizing Peptide (Blocking)
Our Abpromise guarantee covers the use of ab200006 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-P||1/50. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
ab199507 - Rabbit monoclonal IgG (HRP), is suitable for use an as isotype control with this antibody.
|WB||1/5000. Detects a band of approximately 73 kDa (predicted molecular weight: 48 kDa).Can be blocked with TNF Receptor II peptide (ab192471).|
FunctionReceptor with high affinity for TNFSF2/TNF-alpha and approximately 5-fold lower affinity for homotrimeric TNFSF1/lymphotoxin-alpha. The TRAF1/TRAF2 complex recruits the apoptotic suppressors BIRC2 and BIRC3 to TNFRSF1B/TNFR2. This receptor mediates most of the metabolic effects of TNF-alpha. Isoform 2 blocks TNF-alpha-induced apoptosis, which suggests that it regulates TNF-alpha function by antagonizing its biological activity.
Sequence similaritiesContains 4 TNFR-Cys repeats.
modificationsPhosphorylated; mainly on serine residues and with a very low level on threonine residues.
A soluble form (tumor necrosis factor binding protein 2) is produced from the membrane form by proteolytic processing.
Cellular localizationSecreted and Cell membrane.
- Information by UniProt
- CD120b antibody
- p75 antibody
- p75 TNF receptor antibody
All lanes : Anti-TNF Receptor II antibody [EPR1653] (HRP) (ab200006) at 1/5000 dilution
Lane 1 : Jurkat (Human T cell lymphoblast-like cell line) Whole Cell Lysate
Lane 2 : MCF7 (Human breast adenocarcinoma cell line) Whole Cell Lysate
Lane 3 : SW480 (Human colon adenocarcinoma cell line) Whole Cell Lysate
Lane 4 : THP1 (Human acute monocytic leukemia cell line) Whole Cell Lysate
Lysates/proteins at 10 µg per lane.
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 48 kDa
Observed band size: 73 kDa why is the actual band size different from the predicted?
Exposure time: 8 minutes
This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 3% milk before being incubated with ab200006 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.
IHC image of TNF Receptor II staining in a section of formalin-fixed paraffin-embedded normal human kidney*, performed on a Leica BOND. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20mins. The section was then incubated with ab200006 at 1/50 dilution for 15 mins at room temperature. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX. The inset negative control image is taken from an identical assay without primary antibody.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.
*Tissue obtained from the Human Research Tissue Bank, supported by the NIHR Cambridge Biomedical Research Centre
ab200006 has not yet been referenced specifically in any publications.